Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

Monday, June 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the presentation of results from two large prospective studies on endogenous hypercortisolism in patients with resistant hypertension and difficult-to-control type 2 diabetes. The findings were presented by Dr. Ralph DeFronzo at the Endocrine Society Annual Meeting in Chicago. This research highlights important health implications for managing these conditions.
Price reaction · baseline $83.16 (2026-06-15T17:00:00.000Z) · hit during market hours · 4 other CORT headline(s) in the window, move may be shared
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of significant findings at a major conference.
  • Focus on a critical health issue affecting diabetes and hypertension.
  • Involvement of a reputable presenter, Dr. Ralph DeFronzo.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

Presented : Endocrine Society (ENDO) Annual Meeting, 15 June 2026, Chicago, IL
Presenter : Ralph DeFronzo, MD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies appeared first on Corcept Therapeutics .

Frequently Asked Questions

What was presented at the Endocrine Society Annual Meeting?

Results from two large prospective studies on endogenous hypercortisolism.

Who presented the findings at the conference?

Dr. Ralph DeFronzo presented the findings.

What conditions were studied in the research?

The study focused on resistant hypertension and difficult-to-control type 2 diabetes.

When was the presentation made?

The presentation took place on 15 June 2026.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare hypertension type 2 diabetes endocrine society Ralph DeFronzo
Last updated: Jun 15, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
mifepristone+ fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →